Top Ten most popular articles on this week!

pharmafile | December 7, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cancer, Diagnostics, Sanofi, Takeda, brexit 

Takeda’s acquisition of Shire finally got the go-ahead this week as 88% of shareholders voted in favour of French CEO Christophe Weber’s plan which will propel the Japanese firm into 8th position among drugmakers worldwide.

Meanwhile analytics firm GlobalData found that 83% of respondents do not think the UK will be an attractive place for investment into R&D and manufacturing after Brexit. The news comes as German multinational Bayer announced a major restructuring in which 12,000 jobs, representing 10% of the company’s workforce, will go.

Equally French firm Sanofi are set to cut 670 jobs, which seems like nothing in comparison. However in the midst of the gilet jaunes protests which have hit Paris in the past month, the cull seems like another blow.

However our top story of this week covered the development of a new diagnostic test which can detect any cancer type in minutes with 90% accuracy. The discovery could transform the way in which cancer is diagnosed.

10. Takeda shareholders approve $62bn Shire acquisition

Japanese firm Takeda have gained shareholders’ approval for the $62 billion acquisition of the Irish headquartered company Shire Plc.

9. Pfizer’s biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018

Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new data for its biosimilar version of Genentech’s Rituxan/MabThera (rituximab), revealing that the drug met its primary endpoint.

8. Feature – Insider Interview: The diabetes/mental health connection

Michael Connellan, Head of External Affairs at the type 1 diabetes charity JDRF, discusses the results of a recent survey which suggests that more than three quarters of people with diabetes suffer from stress, anxiety attacks or bouts of deep depression.

7. Novartis unveils strong longer-term Kymriah data at ASH 2018

Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah, showing that the treatment demonstrated “strong efficacy with durable responses” in children and adolescent patients with relapsed or refractory (r/r) acute lymphoblastic leukaemia (ALL), and in adult patients with r/r diffuse large B-cell lymphoma (DLBCL).

6. 83% in healthcare say UK will not be attractive for R&D and manufacturing post-Brexit

As the Brexit crisis continues to spiral, new findings from GlobalData reveal that 83% of healthcare professionals in the UK believe that the country will no longer present an attractive destination for healthcare research and manufacturing after it leaves the European Union.

5. Bayer announces major restructure, 12,000 jobs to go

Bayer has announced a major restructure of its operations in 2019 which will see the loss of 12,000 of its 118,200 positions following a number of lawsuits in the wake of its $63 billion buyout of agricultural biotech firm Monsanto.

4. Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018

Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational novel bispecific T cell engager (BiTE) immunotherapies, known as AMG 420 and AMG 330.

3. GSK to acquire oncology biotech Tesaro for $5.1 billion

GlaxoSmithKline is set to acquire US-based oncology biotech Tesaro after both companies signed a definitive agreement with an aggregate cash valuation of $5.1 billion.

2. Sanofi announce cull of 670 French jobs

French pharma giant Sanofi has said that it will cut 670 jobs in France over the next two years. The company currently employs 25,000 employees across France.

1. New diagnostic test can detect any cancer type in minutes with 90% accuracy

Researchers at the University of Queensland have a test which can rapidly detect the presence of cancer in a patient’s body from a blood or biopsy sample with 90% accuracy in trials involving 200 cancer samples.


Related Content

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has …

Pharmanovia acquires CNS portfolio from Sanofi

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a …

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …

Latest content